Karakteristik Pasien dan Penggunaan Kemoterapi Pasien Kanker Paru di RSUD Al-Ihsan
Abstract
Abstract. The prevalence of lung cancer worldwide has been increasing year by year. Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer with a higher incidence compared to Small Cell Lung Cancer (SCLC). Management of NSCLC (Non-Small Cell Lung Cancer) includes several options, one of which is chemotherapy. This study aims to describe the characteristics of gender, age, and the use of first-line chemotherapy regimens in NSCLC patients at RSUD Al-Ihsan in 2023. The study employed a descriptive quantitative method using secondary data from the medical records of pulmonary outpatient clinic patients. Purposive sampling was used, with 63 subjects meeting the inclusion and exclusion criteria. The results showed that the majority of patients were male (67%), with the highest age distribution in the >65 years group (33%). Regarding treatment, carboplatin-based chemotherapy combinations were the dominant regimen, used by 71% of patients, while cisplatin combinations were used by 29% of patients. These findings reflect that the majority of NSCLC patients at RSUD Al-Ihsan are elderly males, with carboplatin being the primary choice for chemotherapy treatment.
Abstrak. Pravelensi kanker paru dunia meningkat dari tahun-ketahun. Kanker Paru Jenis Karsinoma Paru Bukan Sel Kecil (KPKBSK) merupakan jenis kanker paru dengan insidensi lebih tinggi dibandingkan Kanker Paru jenis Karsinoma Sel Kecil (KPKSK). Manajemen KPKBSK terdiri atas beberapa pilihan, salah satunya adalah kemoterapi. Penelitian ini bertujuan untuk menggambarkan karakteristik jenis kelamin, usia, dan penggunaan regimen kemoterapi lini pertama pada pasien KPKBSK di RSUD Al-Ihsan tahun 2023. Penelitian menggunakan metode deskriptif kuantitatif dengan data sekunder dari rekam medis pasien poli paru. Purposive sampling dilakukan, dengan 63 subjek memenuhi kriteria inklusi dan eksklusi. Hasil penelitian menunjukkan bahwa mayoritas pasien adalah laki-laki (67%), dengan distribusi usia terbanyak pada kelompok >65 tahun (33%). Dalam hal terapi, kombinasi kemoterapi berbasis carboplatin menjadi regimen dominan, digunakan oleh 71% pasien, sedangkan kombinasi cisplatin digunakan pada 29% pasien. Temuan ini mencerminkan bahwa pasien KPKBSK di RSUD Al-Ihsan mayoritas adalah laki-laki usia lanjut, dan carboplatin menjadi pilihan utama dalam pengobatan kemoterapi.
References
2. Aldossary, S. A. (2019). Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin. Biomedical and Pharmacology Journal, 12(1), 07–15. https://doi.org/10.13005/bpj/1608
3. Au, P. CM., Lee, A. WM., Lee, V. HF., Wong, I. CK., Hui, R. YM., & Cheung, C.-L. (2024). The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002–2021): a population-based study. The Lancet Regional Health - Western Pacific, 45, 101030. https://doi.org/10.1016/j.lanwpc.2024.101030
4. Global Cancer Incidence Mortality and Prevalence. (2020a). Cancer in Indonesia. https://gco.iarc.fr/today/home
5. Global Cancer Incidence Mortality and Prevalence. (2020b). Lung Cancer. https://gco.iarc.fr/today/home
6. Hamdani, A. F., Purbaningsih, W., & Nalapraya, W. Y. (2023). Karakteristik demografi dan klinikopatologi pasien kanker paru di RSUD Al−Ihsan. Jurnal Riset Kedokteran, 97–102. https://doi.org/10.29313/jrk.v3i2.2959
7. Huang, C.-Y., Cheng, M., Lee, N.-R., Huang, H.-Y., Lee, W.-L., Chang, W.-H., & Wang, P.-H. (2020). Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. International Journal of Environmental Research and Public Health, 17(7), 2213. https://doi.org/10.3390/ijerph17072213
8. Jiang, S., Huang, L., Zhen, H., Jin, P., Wang, J., & Hu, Z. (2021). Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer, 21(1), 1308. https://doi.org/10.1186/s12885-021-09034-6
9. Kementerian Kesehatan Republik Indonesia. (2017). Pedoman nasional pelayanan kedokteran kanker paru.
10. Kusumawardani, N., Nalapraya, W. Y., & Alie, I. R. (2022). Karakteristik dan faktor risiko pasien kanker paru di RSUD Al-Ihsan Provinsi Jawa Barat tahun 2022. Bandung Conference Series: Medical Science. https://doi.org/https://doi.org/10.29313/bcsms.v4i1.10372
11. Laconi, E., Marongiu, F., & DeGregori, J. (2020). Cancer as a disease of old age: changing mutational and microenvironmental landscapes. British Journal of Cancer, 122(7), 943–952. https://doi.org/10.1038/s41416-019-0721-1
12. Mollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021). Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Translational Oncology, 14(5), 101056. https://doi.org/10.1016/j.tranon.2021.101056
13. O’Keeffe, L. M., Taylor, G., Huxley, R. R., Mitchell, P., Woodward, M., & Peters, S. A. E. (2018). Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open, 8(10), e021611. https://doi.org/10.1136/bmjopen-2018-021611
14. Ratnakaram, K., Yendamuri, S., Groman, A., & Kalvapudi, S. (2024). Sex-Based Differences in Lung Cancer Incidence: A Retrospective Analysis of Two Large US-Based Cancer Databases. Cancers, 16(19), 3244. https://doi.org/10.3390/cancers16193244
15. Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018). Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.00586
16. Sheehan, D. F., Criss, S. D., Chen, Y., Eckel, A., Palazzo, L., Tramontano, A. C., Hur, C., Cipriano, L. E., & Kong, C. Y. (2019). Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Medicine, 8(1), 94–103. https://doi.org/10.1002/cam4.1896
17. Su, C., Zhou, F., Shen, J., Zhao, J., & O’Brien, M. (2017). Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) translocations – Still a daily challenge. European Journal of Cancer, 83, 266–278. https://doi.org/10.1016/j.ejca.2017.07.002
18. White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Jane Henley, S. (2014). Age and Cancer Risk. American Journal of Preventive Medicine, 46(3), S7–S15. https://doi.org/10.1016/j.amepre.2013.10.029
19. Wozniak, A. J., Kosty, M. P., Jahanzeb, M., Brahmer, J. R., Spigel, D. R., Leon, L., Fish, S., Flick, E. D., Hazard, S. J., & Lynch, T. J. (2015). Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study. Clinical Oncology, 27(4), 187–196. https://doi.org/10.1016/j.clon.2014.12.002
20. Yu, X. Q., Yap, M. L., Cheng, E. S., Ngo, P. J., Vaneckova, P., Karikios, D., Canfell, K., & Weber, M. F. (2022). Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. Journal of Thoracic Oncology, 17(5), 688–699. https://doi.org/10.1016/j.jtho.2022.01.016
